Efficacy of immunotherapy targeting the neoantigen derived from epidermal growth factor receptor T790M/C797S mutation in non–small cell lung cancer

• Published in: Cancer science Vol. 111; no. 8; pp. 2736 - 2746
• Main Authors: Akazawa, Yu, Saito, Yuki, Yoshikawa, Toshiaki, Saito, Keigo, Nosaka, Kazuto, Shimomura, Manami, Mizuno, Shoichi, Nakamoto, Yasunari, Nakatsura, Tetsuya
• Format: Journal Article
• Language: English
• Published: England John Wiley & Sons, Inc 01.08.2020; John Wiley and Sons Inc
• Subjects: Acrylamides - pharmacology; Acrylamides - therapeutic use; Aniline Compounds - pharmacology; Aniline Compounds - therapeutic use; Animals; Antibodies; Antigens; Antigens, Neoplasm - administration & dosage; Antigens, Neoplasm - genetics; Antigens, Neoplasm - immunology; C797S mutation; Cancer therapies; Cancer Vaccines - administration & dosage; Cancer Vaccines - genetics; Cancer Vaccines - immunology; Carcinoma, Non-Small-Cell Lung - drug therapy; Carcinoma, Non-Small-Cell Lung - genetics; Carcinoma, Non-Small-Cell Lung - immunology; Cell Line, Tumor; Chemotherapy; Cloning; Cytotoxicity; Drug Resistance, Neoplasm - genetics; Drug Resistance, Neoplasm - immunology; EGFR T790M; Enzyme-linked immunosorbent assay; Enzymes; Epidermal growth factor; Epidermal growth factor receptors; Epitopes, T-Lymphocyte - genetics; Epitopes, T-Lymphocyte - immunology; ErbB Receptors - antagonists & inhibitors; ErbB Receptors - genetics; ErbB Receptors - immunology; Histocompatibility antigen HLA; HLA-A2 Antigen - genetics; HLA-A2 Antigen - immunology; Humans; Immunotherapy; Immunotherapy - methods; Interferon; Kinases; Lung cancer; Lung Neoplasms - drug therapy; Lung Neoplasms - genetics; Lung Neoplasms - immunology; Lymphocytes T; Medical prognosis; Methionine; Mice; Mice, Knockout; Mutation; neoantigen; Neoantigens; Non-small cell lung carcinoma; non–small cell lung cancer; Original; Patients; Penicillin; Peptides; Peripheral blood mononuclear cells; Protein Kinase Inhibitors - pharmacology; Protein Kinase Inhibitors - therapeutic use; Protein-tyrosine kinase; Serine; Small cell lung carcinoma; T-Lymphocytes, Cytotoxic - immunology; Threonine; Vaccines, Subunit - administration & dosage; Vaccines, Subunit - genetics; Vaccines, Subunit - immunology; Japan; C797S mutation; neoantigen; non-small cell lung cancer; EGFR T790M; immunotherapy

Lung cancer is the leading cause of cancer‐related deaths worldwide. Epidermal growth factor receptor‐tyrosine kinase inhibitors (EGFR‐TKI) often have good clinical activity against non–small cell lung cancer (NSCLC) with activating EGFR mutations. Osimertinib, which is a third‐generation EGFR‐TKI,...